BNGO vs. PDEX, ENTX, CLGN, CVM, LABP, CKPT, ZVIA, PTWO, MNOV, and LENZ
Should you be buying Bionano Genomics stock or one of its competitors? The main competitors of Bionano Genomics include Pro-Dex (PDEX), Entera Bio (ENTX), CollPlant Biotechnologies (CLGN), CEL-SCI (CVM), Landos Biopharma (LABP), Checkpoint Therapeutics (CKPT), Zevia PBC (ZVIA), Pono Capital Two (PTWO), MediciNova (MNOV), and LENZ Therapeutics (LENZ). These companies are all part of the "medical" sector.
Bionano Genomics (NASDAQ:BNGO) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, community ranking, analyst recommendations, earnings, risk, profitability and media sentiment.
In the previous week, Pro-Dex had 2 more articles in the media than Bionano Genomics. MarketBeat recorded 5 mentions for Pro-Dex and 3 mentions for Bionano Genomics. Pro-Dex's average media sentiment score of 0.94 beat Bionano Genomics' score of 0.93 indicating that Pro-Dex is being referred to more favorably in the news media.
Pro-Dex has higher revenue and earnings than Bionano Genomics. Bionano Genomics is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.
Bionano Genomics presently has a consensus price target of $4.00, indicating a potential upside of 270.54%. Given Bionano Genomics' higher probable upside, equities analysts clearly believe Bionano Genomics is more favorable than Pro-Dex.
Bionano Genomics has a beta of 2.4, meaning that its stock price is 140% more volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.
Bionano Genomics received 15 more outperform votes than Pro-Dex when rated by MarketBeat users. Likewise, 64.80% of users gave Bionano Genomics an outperform vote while only 60.74% of users gave Pro-Dex an outperform vote.
Pro-Dex has a net margin of 4.13% compared to Bionano Genomics' net margin of -605.26%. Pro-Dex's return on equity of 6.50% beat Bionano Genomics' return on equity.
11.4% of Bionano Genomics shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 1.7% of Bionano Genomics shares are owned by company insiders. Comparatively, 42.6% of Pro-Dex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Pro-Dex beats Bionano Genomics on 11 of the 17 factors compared between the two stocks.
Get Bionano Genomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bionano Genomics Competitors List
Related Companies and Tools
